FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and ...
FDA Approves Nasal Spray for Depression - Newsweek
1 day ago · The FDA has now expanded its approval to include the standalone use of the nasal spray for adults with treatment-resistant major depressive disorder. A stock photo showing a woman's face in shadow.
FDA Approves Spravato Nasal Spray as a Standalone Treatment …
1 day ago · One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it more difficult to be treated by traditional oral antidepressants. The FDA approved Spravato (esketamine) CIII nasal spray today as a first-of-its-kind, standalone treatment ...
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
17 hours ago · WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had
FDA allows standalone use of nasal spray antidepressant Spravato ...
1 day ago · The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression.
Ketamine Nasal Spray Approved as Standalone Treatment for …
14 hours ago · An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato ...
FDA approves Spravato, first monotherapy nasal spray to treat
2 days ago · The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive ...
FDA approves new nasal spray medication for treatment-resistant ...
The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have...
SPRAVATO® (esketamine): A Prescription Nasal Spray
SPRAVATO®, the only FDA-approved nasal spray for adults with treatment-resistant depression, reduces depression symptoms when two or more oral antidepressants haven't worked. SPRAVATO® can be taken with or without an oral antidepressant.
FDA approves Johnson & Johnson’s nasal spray for depression …
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The ...